Qian Ding
A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter
Ding, Qian; Cai, Jianghong; Jin, Li; Hu, Wei; Song, Wu; Rose, Peter; Tang, Zhiyuan; Zhan, Yangyang; Bao, Leilei; Lei, Wei; Zhu, Yi Zhun
Authors
Jianghong Cai
Li Jin
Wei Hu
Wu Song
Dr Peter Rose Peter.Rose@nottingham.ac.uk
ASSISTANT PROFESSOR
Zhiyuan Tang
Yangyang Zhan
Leilei Bao
Wei Lei
Yi Zhun Zhu
Abstract
SMYD3 (SET and MYND domain-containing 3) is a histone lysine methyltransferase highly expressed in different types of cancer(s) and is a promising epigenetic target for developing novel antitumor therapeutics. No selective inhibitors for this protein have been developed for cancer treatment. Therefore, the current study describes developing and characterizing a novel small molecule ZYZ384 screened and synthesized based on SMYD3 structure. Virtual screening was initially used to identify a lead compound and followed up by modification to get the novel molecules. Several technologies were used to facilitate compound screening about these novel molecules' binding affinities and inhibition activities with SMYD3 protein; the antitumor activity has been assessed in vitro using various cancer cell lines. In addition, a tumor-bearing nude mice model was established, and the activity of the selected molecule was determined in vivo. Both RNA-seq and chip-seq were performed to explore the antitumor mechanism. This work identified a novel small molecule ZYZ384 targeting SMYD3 with antitumor activity and impaired hepatocellular carcinoma tumor growth by reducing H3K4 trimethylation of the Rac1 promoter triggering the tumor cell cycle arrest through the AKT pathway.
Citation
Ding, Q., Cai, J., Jin, L., Hu, W., Song, W., Rose, P., Tang, Z., Zhan, Y., Bao, L., Lei, W., & Zhu, Y. Z. (2024). A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4 trimethylation of the Rac1 promoter. MedComm, 5(10), Article e711. https://doi.org/10.1002/mco2.711
Journal Article Type | Article |
---|---|
Acceptance Date | Aug 29, 2024 |
Online Publication Date | Sep 15, 2024 |
Publication Date | 2024-10 |
Deposit Date | Sep 23, 2024 |
Publicly Available Date | Sep 26, 2024 |
Journal | MedComm |
Electronic ISSN | 2688-2663 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 5 |
Issue | 10 |
Article Number | e711 |
DOI | https://doi.org/10.1002/mco2.711 |
Keywords | antitumor; H3K4me3; Rac1 promoter; small molecule; SMYD3 ZYZ384 |
Public URL | https://nottingham-repository.worktribe.com/output/39730759 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1002/mco2.711 |
Files
MedComm - 2024 - Ding - A novel small molecule ZYZ384 targeting SMYD3 for hepatocellular carcinoma via reducing H3K4
(6.5 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Editorial: Novel compounds from chemistry to druggable candidates
(2024)
Journal Article
Update on the global prevalence and severity of kiwifruit allergy: a scoping review
(2023)
Journal Article
The Impact of Drugs on Hydrogen Sulfide Homeostasis in Mammals
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search